News
FOLD
10.55
+1.34%
0.14
Weekly Report: what happened at FOLD last week (0708-0712)?
Weekly Report · 10h ago
Amicus (FOLD) Gets a Buy from Stifel Nicolaus
TipRanks · 07/08 11:15
Weekly Report: what happened at FOLD last week (0701-0705)?
Weekly Report · 07/08 10:01
Weekly Report: what happened at FOLD last week (0624-0628)?
Weekly Report · 07/01 10:02
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
NASDAQ · 06/26 13:47
Weekly Report: what happened at FOLD last week (0617-0621)?
Weekly Report · 06/24 10:05
The Math Shows SMLF Can Go To $72
NASDAQ · 06/20 11:25
Weekly Report: what happened at FOLD last week (0610-0614)?
Weekly Report · 06/17 10:01
Weekly Report: what happened at FOLD last week (0603-0607)?
Weekly Report · 06/10 10:02
Amicus Therapeut: Statement of changes in beneficial ownership of securities
Press release · 06/08 00:07
Weekly Report: what happened at FOLD last week (0527-0531)?
Weekly Report · 06/03 10:04
3 Biotech Names Under $10 I Own
Bret Jensen owns three biotech names that currently trade under $10 a share. Two of these are quickly moving towards profitability. The other is cash rich and has several partnerships with large pharma companies. Amicus Therapeutics, Inc. And Aurinia Pharmaceuticals Inc. Are among the names he owns in his portfolio.
Seeking Alpha · 06/02 14:18
Validea Detailed Fundamental Analysis - FOLD
NASDAQ · 05/31 20:11
Wells Fargo Initiates Coverage of Amicus Therapeutics (FOLD) with Overweight Recommendation
NASDAQ · 05/31 00:13
Amicus Therapeutics Initiated at Overweight by Wells Fargo
Dow Jones · 05/30 15:17
Amicus Therapeutics Price Target Announced at $18.00/Share by Wells Fargo
Dow Jones · 05/30 15:17
Wells Fargo Initiates Coverage On Amicus Therapeutics with Overweight Rating, Announces Price Target of $18
Benzinga · 05/30 15:07
AMICUS THERAPEUTICS INC <FOLD.O>: WELLS FARGO INITIATES COVERAGE WITH OVERWEIGHT RATING; TARGET PRICE $18
Reuters · 05/30 10:57
Buy Rating Affirmed: Amicus’s Undervalued Pompe Treatment and Strong Fabry Drug Market Position Drive Positive Outlook
TipRanks · 05/30 10:01
More
Webull provides a variety of real-time FOLD stock news. You can receive the latest news about Amicus Therapeut through multiple platforms. This information may help you make smarter investment decisions.
About FOLD
Amicus Therapeutics, Inc. is a biotechnology company, which is focused on discovering, developing, and delivering novel medicines for rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a novel treatment designed to improve uptake of active enzyme into key disease relevant tissues for adults living with late-onset Pompe disease. As an orally administered monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A (alpha-Gal A) enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice (GLP) cell-based amenability assay. Pombiliti + Opfolda consists of a uniquely engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance lysosomal uptake, administered in combination with miglustat that functions as an enzyme stabilizer.